Advertisement

Topics

NOXXON Pharma AG Company Profile

03:30 EST 16th December 2018 | BioPortfolio

Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing on the development of Spiegelmers® for the treatment of inflammatory diseases and hematological indications. NOXXON possesses a broad patent estate and has access to a readily scalable GMP production. In addition to its in-house programs, NOXXON discovers and develops Spiegelmers® in collaboration with partners from the pharmaceutical industry, including Eli Lilly and Hoffmann La-Roche. The business strategy of NOXXON is to broaden this range of collaborations through co-development and licensing agreements for the proprietary clinical and pre-clinical products. Currently the company has two compounds in clinical development.

Location

Max-Dohrn-Str. 8-10
Berlin
D-10589
Germany

Contact

Phone: 49 (0)30 / 72 62 47-0
Fax: 49 (0)30 / 72 62 47-225
Email: ebrimacombe@noxxon.net


News Articles [477 Associated News Articles listed on BioPortfolio]

NOXXON Pharma: Top-Line-Daten zur Wirksamkeit aus dem zweiten Teil der Phase I NOX-A12-Studie

Bad Marienberg (www.anleihencheck.de) - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen fokussiert auf die Verbesserung von Krebstherapien durch gezielte Einwirkung...

Noxxon Pharma: NOX-A12 mit "klaren klinischen Nutzen für die Patienten"

Noxxon Pharma hat am Freitag wie angekündigt Daten zu klinischen Studien mit ihren Flaggschiff-Medikamentenprojekt NOX-A12 vorgelegt. Getestet wurde das Mittel in Kombination mit dem Medikament Key.....

Noxxon Pharma: Neue Studie mit NOX-A12 soll 2019 starten - Aktie gewinnt

Für die Noxxon Pharma Aktie geht es heute spürbar nach oben. Am Handelssegment Euronext Growth der Pariser Börse liegt die Biotechaktie mit mehr als 7 Prozent im Plus bei 1,48 Euro, das Tageshoch i...

Noxxon Pharma legt Halbjahreszahlen vor

Noxxon Pharma hat am Donnerstag Zahlen für die erste Hälfte des laufenden Jahres vorgelegt. Das Biotechunternehmen meldet einen Verlustanstieg von 2,23 Millionen Euro auf 4,05 Millionen Euro, basie....

Noxxon Pharma: Rekrutierungsphase für NOX-A12 braucht mehr Zeit

Noxxon Pharma benötigt bei einer laufenden klinischen Studie mit dem Krebsmedikamentenkandidaten NOX-A12 zwar mehr Zeit bei der Rekrutierung der Patienten, rechnet aber weiterhin damit, im vierten .....

Aram Mangasarian explains the elegant mirror image technology of NOXXON Pharma for extracellular targets

In this episode of PharmaTelevision News Review, filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to Aram Mangasarian, CBO of NOXXON Pharma AG.

Noxxon: Aktie der DEWB-Beteiligung vom Handel ausgesetzt

Für Noxxon Pharma steht ein wichtiger Tag an: Das Biotechunternehmen wird heute auf dem ESMO Immuno-Oncology-Kongress in der Schweiz Daten zum Flaggschiffprojekt NOX-A12 vorlegen. Die Präsentation ....

NOXXON Pharma: Aktie mit Kurssprung - Daten angekündigt

NOXXON Pharma hat am Montag die Teilnahme an dem ESMO Immuno-Oncology-Kongress vom 13.-16. Dezember 2018 in der Schweiz angekündigt. Das Unternehmen wird auf dem Kongress Daten zum Flaggschiffproje.....

Drugs and Medications [238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [21 Associated PubMed Articles listed on BioPortfolio]

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the dea...

Clinical Trials [85 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [783 Associated Companies listed on BioPortfolio]

NOXXON Pharma AG

Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing on the development of Spiegelmers® for the treatment of inflammatory diseases and hematological...

Noxxon Global Service Informática Ltda

Nil

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

Laurantis Pharma Oy

Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies, ...

More Information about "NOXXON Pharma AG" on BioPortfolio

We have published hundreds of NOXXON Pharma AG news stories on BioPortfolio along with dozens of NOXXON Pharma AG Clinical Trials and PubMed Articles about NOXXON Pharma AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NOXXON Pharma AG Companies in our database. You can also find out about relevant NOXXON Pharma AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record